Financhill
Back

BeiGene 10K Form

Sell
45

BGNE
BeiGene

Last Price:
178.64
Seasonality Move:
-1.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BGNE News And Ratings

See the #1 stock for the next 7 days that we like better than BGNE

BGNE Financial Statistics

Sales & Book Value

Annual Sales: $2.46B
Cash Flow: $-388.55M
Price / Cash Flow: 0
Annual Sales: $33.82
Price / Book: 5.31

Profitability

EPS (TTM): -8.58000
Net Income (TTM): $-881.71M
Gross Margin: $2.08B
Return on Equity: -22.45%
Return on Assets: -15%

BeiGene Earnings Forecast

Key BeiGene Financial Ratios

  • The Gross Profit Margin over the past 11 years for BGNE is 84.55%.
  • The Selling, General & Administrative Expenses for BGNE have been equal to 61.19% of Gross Profit Margin.
  • The Research & Development expenses have been 72.34% of Revenue.
  • The Interest Expense is -42.19% of Operating Income.
  • The Net Earning history of BGNE is -35.86% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 3 years.

BeiGene Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: BGNE
CUSIP: 07725L
Website: beigene.com

Debt

Debt-to-Equity Ratio: 0.25
Current Ratio: 2.32
Quick Ratio: 1.97

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BGNE Technical Analysis vs Fundamental Analysis

Sell
45
BeiGene (BGNE) is a Sell

Is BeiGene a Buy or a Sell?

  • BeiGene stock is rated a Sell
    The current BeiGene [BGNE] share price is $179.69. The Score for BGNE is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.